FDA advisory panelist outlines issues with aducanumab's approval for Alzheimer's disease

(American College of Physicians) Despite near unanimous objection from its advisory panel, the US Food and Drug Administration (FDA) granted aducanumab approval to treat Alzheimer's disease on June 7, 2021. In a commentary published in Annals of Internal Medicine, a member and former Chair of the advisory panel and an aducanumab site investigator explain why this unprecedented " accelerated approval " is problematic for clinical research and patient care.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news